Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLAT-06: CD19-specific CAR T Cells for CD19+ Leukemia or Lymphoma
NCT03684889Phase 1Active, not recruiting
- Sponsor
- Seattle Children's
- Start
- Nov 2018
- Primary completion
- Feb 2021
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of SCRI-huCAR19v1 and SCRI-CAR19 in leukemia and lymphoma (2 arms), sponsored by Seattle Children's. Primary endpoints: Adverse Events at 30 days and Objective Response Rate at 63 days. Started Nov 2018; status: active, not recruiting.
02
Drugs
SCRI-huCAR19v1SCRI-CAR19
03
Conditions
leukemialymphoma
Beyond the preview
Go deeper on NCT03684889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03684889.